GSK Glaxo Smith Clinical Trials

Company details

Status: Public
HQ: 637 r Aulnois, Saint Amand les Eaux, 59 59230, FR, SAINT-AMAND LES EAUX
Employees: 30
Programs: 205
Drugs: 194
Patents: 0

Official website ↗ All projects Drug pipeline News & analysis

Recent coverage

GSK’s Blenrep returns to the US market after FDA approves resubmission Jun 7, 2026
Moderna mRNA-1083 Phase 3 data show stronger flu and COVID immune response Jun 7, 2026

View all news & analysis →

Recent trial activity

8 updates

Latest clinical program signals indexed for GSK Glaxo Smith.

Trial registry

211 studies

2023-503219-14-01
218224

Phase 3 active small_molecule

systemic sclerosis associated interstitial lung disease

CTIS ↗
2023-503428-24-00
JEMPERLI 500 mg concentrate for solution for infusion

Phase 2 active small_molecule

Neoplasms, Head and Neck

CTIS ↗
2023-504238-23-00
Placebo for Bepirovirsen Solution for Injection 150 mg/mL

Phase 3 active small_molecule

Hepatitis B, Chronic

CTIS ↗
2023-504239-41-00
Placebo for Bepirovirsen Solution for Injection 150 mg/mL

Phase 3 active small_molecule

Hepatitis B, Chronic

CTIS ↗
2023-504301-37-00
NaCl 0.9% solution

Phase 2 active small_molecule

Meningitis, Meningococcal

CTIS ↗
2023-504454-35-00
Niraparib Placebo Tablets

Phase 3 active small_molecule

Neoplasms, Breast

CTIS ↗
2023-504753-12-00
213823

Phase 3 active small_molecule

Lung Cancer, Non-Small Cell

CTIS ↗
2023-505057-40-00
213824

Phase 2 active small_molecule

Lung Cancer, Non-Small Cell

CTIS ↗
2023-505083-11-01
219867

Phase 2 active small_molecule

Alzheimer's Disease

CTIS ↗
2023-505203-23-01
212895

Phase 3 active other

Severe asthma with an eosinophilic phenotype

CTIS ↗
2023-505414-15-00
Locally Sourced 0.9% Sodium Chloride

Phase 2 active small_molecule

Dermatitis, Atopic

CTIS ↗
2023-505894-33-00
213403

Phase 2 active small_molecule

Lung Cancer, Non-Small Cell

CTIS ↗
2023-506063-34-00
209626 (DreaMM 12)

Phase 1 active other

Relapsed/Refractory Multiple Myeloma

CTIS ↗
2023-506449-40-00
217043

Phase 2 active small_molecule

Infections, Meningococcal

CTIS ↗
2023-506867-33-01
206882

Phase 2 active other

Chronic Hepatitis B

CTIS ↗
2023-506877-37-00
207499

Phase 3 active small_molecule

Relapsed/Refractory Multiple Myeloma

CTIS ↗
2023-506880-32-01
221531

Phase 1 active other

Pulmonary Disease, Chronic Obstructive

CTIS ↗
2023-507060-39-00
209664

Phase 1 active other

Multiple Myeloma

CTIS ↗
2023-507475-21-00
213410

Phase 3 active small_molecule

Lung Cancer, Non-Small Cell

CTIS ↗
2023-507503-62-00
0.9% Sodium Chloride Injection

Phase 2 active small_molecule

Non-alcoholic Fatty Liver Disease

CTIS ↗
2023-507839-38-00
220104

Phase 1 active other

Tuberculosis

CTIS ↗
2023-508018-41-00
SRA-MMB-4365/219627

Phase 2 active other

Primary Myelofibrosis (PMF), Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

CTIS ↗
2023-508213-16-00
209628

Phase 2 active other

Multiple Myeloma

CTIS ↗
2023-508279-36-00
219728

Phase 1 active other

Healthy volunteers

CTIS ↗
2023-508443-40-00
213400

Phase 3 active small_molecule

Lung Cancer, Non-Small Cell

CTIS ↗
2023-508474-29-00
Locally Sourced 0.9% Sodium Chloride

Phase 2 active small_molecule

Dermatitis, Atopic

CTIS ↗
2023-508613-17-00
221530

Phase 3 active small_molecule

Neoplasms, Head and Neck

CTIS ↗
2023-508962-14-00
207495

Phase 3 active small_molecule

Relapsed/Refractory Multiple Myeloma

CTIS ↗
2023-509001-76-00
220735

Phase 3 active small_molecule

Asthma

CTIS ↗
2023-509026-21-00
219871

Approved active small_molecule

severe asthma

CTIS ↗
2023-509027-41-00
222110

Phase 1 active other

Hepatitis B, Chronic

CTIS ↗
2023-509146-35-00
Benlysta 200 mg solution for injection in pre-filled pen.

Approved active small_molecule

Systemic Lupus Erythematosus

CTIS ↗
2023-509370-39-00
Benlysta 200 mg solution for injection in pre-filled pen.

Phase 3 active small_molecule

connective tissue diseases

CTIS ↗
2023-509371-16-00
Placebo to Match GSK3915393 Tablet

Phase 2 active small_molecule

Idiopathic Pulmonary Fibrosis

CTIS ↗
2023-509413-37-00
200908

Phase 2 active small_molecule

Systemic Lupus Erythematosus

CTIS ↗
2023-509414-11-00
217228

Phase 1 active other

Neoplasms

CTIS ↗
2023-509455-13-00
219815

Approved active small_molecule

Respiratory Syncytial Virus Infections

CTIS ↗
2023-509550-55-00
208887

Phase 2 active small_molecule

Multiple Myeloma

CTIS ↗
2023-509583-22-00
JEMPERLI 500 mg concentrate for solution for infusion

Phase 2 active small_molecule

Neoplasms, Rectal

CTIS ↗
2023-509588-25-00
219231

Phase 2 active small_molecule

Hepatitis B

CTIS ↗
2023-509684-24-00
Placebo to Match GSK3965193 Tablets

Phase 2 active small_molecule

Hepatitis B

CTIS ↗
2023-509762-38-00
222090

Phase 3 active small_molecule

Respiratory Syncytial Virus Infections

CTIS ↗
2023-509915-10-00
209627(DREAMM 13)

Phase 1 active other

Relapsed or Refractory Multiple Myeloma

CTIS ↗
2023-510019-20-00
217102

Phase 3 active small_molecule

Relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) receiving standard of care (SoC) therapy

CTIS ↗
2023-510020-68-00
Buffer S9b Solution for suspension for injection

Phase 2 active small_molecule

Hepatitis B, Chronic

CTIS ↗
2023-510110-36-00
MEPOLIZUMAB

Phase 3 active small_molecule

Hypereosinophilic syndrome (HES)

CTIS ↗
2023-510190-34-00
222253

Phase 3 active small_molecule

Respiratory Syncytial Virus Infections

CTIS ↗
2023-510196-59-00
217848

Phase 3 active small_molecule

Respiratory Syncytial Virus Infections

CTIS ↗
2023-510230-84-00
206785

Phase 3 active small_molecule

Severe asthma with an eosinophilic phenotype

CTIS ↗
2023-510340-20-00
221615

Phase 1 active other

Systemic Lupus Erythematosus

CTIS ↗
2023-510346-25-00
217013

Phase 3 active small_molecule

Hypereosinophilic Syndrome (HES)

CTIS ↗
2023-510537-28-00
207503

Phase 3 active small_molecule

Multiple Myeloma

CTIS ↗
2024-510571-37-00
NaCl solution

Phase 2 active small_molecule

Herpes Simplex

CTIS ↗
2024-510663-34-00
Dectova 10 mg/mL solution for infusion

Phase 2 active small_molecule

Influenza, Human

CTIS ↗
2024-511071-16-00
213406

Phase 1 active small_molecule

Solid Tumours

CTIS ↗
2024-511220-14-00
219729

Phase 1 active other

Mild Asthma

CTIS ↗
2024-511350-41-00
JEMPERLI 500 mg concentrate for solution for infusion

Phase 2 active small_molecule

Relapsed/Refractory Tumors

CTIS ↗
2024-511596-15-00
222291

Phase 2 active other

Liver Diseases, Alcoholic

CTIS ↗
2024-512291-34-00
212496

Phase 3 active small_molecule

Respiratory Syncytial Virus Infections

CTIS ↗
2024-512352-38-00
Buffer S9b Solution for suspension for injection

Phase 2 active small_molecule

Hepatitis B, Chronic

CTIS ↗
2024-512730-15-00
114055

Phase 2 active small_molecule

Systemic Lupus Erythematosus

CTIS ↗
2024-512846-41-00
222261

Phase 1 active other

Respiratory Syncytial Virus Infections

CTIS ↗
2024-513018-36-00
221672

Phase 3 active small_molecule

Lung Diseases, Interstitial

CTIS ↗
2024-513441-36-00
222892

Phase 2 active small_molecule

MMRp/ MSS colon cancer

CTIS ↗
2024-513574-21-00
208850

Phase 1 active other

Neoplasms

CTIS ↗
2024-513663-10-01
A Phase 1 study of GSK5764227 in participants with advanced solid tumors

Phase 1 active other

Neoplasms

CTIS ↗
2024-513860-25-00
222730

Phase 2 active other

Ovarian Neoplasms

CTIS ↗
2024-514186-18-00
221458

Phase 1 active other

Systemic Lupus Erythematosus

CTIS ↗
2024-515247-28-00
104317

Phase 3 active other

Hypereosinophilic Syndrome

CTIS ↗
2024-515868-31-00
213997 (VNS 20-001)

Phase 3 active small_molecule

Varicella

CTIS ↗
2024-515869-33-00
213998 (VNS 20-002)

Phase 3 active small_molecule

Varicella

CTIS ↗
2024-516030-35-00
214828

Phase 3 active small_molecule

Multiple myeloma

CTIS ↗
2024-516095-15-00
221362

Phase 1 active other

Kidney Disease

CTIS ↗
2024-516635-27-00
214002 (VNS 20-004)

Phase 3 active small_molecule

Varicella

CTIS ↗
2024-517147-31-00
223559

Phase 2 active small_molecule

Tumours, Gynecological

CTIS ↗
2024-518225-15-00
Reblozyl 75 mg powder for solution for injection

Phase 2 active small_molecule

Myelofibrosis

CTIS ↗
2024-518321-15-00
Placebo for GSK5784283.

Phase 2 active small_molecule

Asthma

CTIS ↗
2024-518840-18-00
223105

Phase 3 active small_molecule

Varicella

CTIS ↗
2024-519319-32-00
sterile saline solution (0.9% w/v solution of NaCl in water).

Phase 2 active small_molecule

Urinary Tract Infections

CTIS ↗
2024-519549-31-00
220030

Phase 3 active small_molecule

Invasive meningococcal disease (IMD)

CTIS ↗
2024-519721-37-00
JEMPERLI 500 mg concentrate for solution for infusion

Phase 2 active small_molecule

Neoplasms, Colorectal

CTIS ↗
2024-519730-23-00
224083

Phase 2 active small_molecule

Respiratory Syncytial Virus Infections

CTIS ↗
2024-519928-24-00
223584

Phase 2 active other

Myelodysplastic Syndrome

CTIS ↗
2024-519976-19-00
223529

Phase 3 active other

Asthma with type 2 inflammation characterized by an eosinophilic phenotype

CTIS ↗
2024-520197-36-00
219590

Phase 2 active small_molecule

Neoplasms

CTIS ↗
2024-520417-41-00
222725

Phase 3 active small_molecule

Chronic Obstructive Pulmonary Disease

CTIS ↗
2025-520672-26-00
223675

Phase 2 active other

Gastrointestinal Neoplasms

CTIS ↗
2025-521107-42-00
223646

Phase 2 active other

Alzheimer's Disease

CTIS ↗
2025-521108-23-00
224295

Phase 3 active small_molecule

Chronic Obstructive Pulmonary Disease

CTIS ↗
2025-521581-10-00
223050

Phase 2 active other

Neoplasms, Prostate

CTIS ↗
2025-521627-78-00
223674

Phase 3 active small_molecule

Neoplasms, Lung

CTIS ↗
2025-522274-37-00
300148

Phase 2 active small_molecule

Neoplasms

CTIS ↗
2025-522278-35-00
300356

Phase 2 active small_molecule

Influenza, Human

CTIS ↗
2025-522318-21-00
224035

Phase 2 active other

Neoplasms, Colorectal

CTIS ↗
2025-522599-97-00
300336

Phase 2 active small_molecule

Influenza, Human

CTIS ↗
2025-522916-17-00
222778

Phase 1 active other

Urinary Tract Infections

CTIS ↗
2025-522932-15-00
300134

Phase 1 active other

Systemic Lupus Erythematosus

CTIS ↗
2025-523117-28-00
224317

Phase 2 active small_molecule

Relapsed or Refractory Multiple Myeloma

CTIS ↗
2025-524165-25-00
300163

Phase 1 active other

Neoplasms

CTIS ↗
2025-524598-17-00
300889

Approved active small_molecule

Incident dementia

CTIS ↗
2025-524944-37-00
DAN-ZOSTER

Approved active small_molecule

Herpes Zoster

CTIS ↗
2025-525073-37-00
221377

Phase 1 active other

Autosomal Dominant Polycystic Kidney Disease

CTIS ↗
NCT00067457
alosetron

Phase 3 completed small_molecule

Irritable Colon

CT.gov ↗
NCT00090103
dutasteride 0.5mg once daily for 4 years

Phase 3 completed small_molecule

Prostatic Hyperplasia

CT.gov ↗
NCT00102726
SB497115

Phase 2 completed small_molecule

Thrombocytopaenia

CT.gov ↗
NCT00102739
SB497115

Phase 2 completed small_molecule

Purpura, Thrombocytopaenic, Idiopathic

CT.gov ↗
NCT00116831
Glipizide

Phase 3 completed small_molecule

Atherosclerosis

CT.gov ↗
NCT00120900
GW406381

Phase 3 completed small_molecule

Osteoarthritis, Knee

CT.gov ↗
NCT00122681
Cervarix™

Phase 3 completed mab

Infections, Papillomavirus

CT.gov ↗
NCT00169442
Tritanrix™-HepB/Hiberix™ Kft.

Phase 3 completed mab

Whole Cell Pertussis

CT.gov ↗
NCT00169572
Aprepitant

Phase 2 completed small_molecule

Nausea and Vomiting

CT.gov ↗
NCT00228917
Tritanrix-HepB/Hib-MenAC

Phase 3 completed mab

Whole Cell Pertussis

CT.gov ↗
NCT00240526
Engerix™ -B

Approved completed mab

Hepatitis B

CT.gov ↗
NCT00274690
GW679769

Phase 2 completed small_molecule

Postoperative Nausea and Vomiting

CT.gov ↗
NCT00289198
FF

Phase 3 completed small_molecule

Rhinitis, Allergic, Perennial

CT.gov ↗
NCT00291967
DTPw-HBV/Hib-MenAC conjugate vaccine

Phase 2 completed mab

Diphtheria

CT.gov ↗
NCT00343486
Solabegron

Phase 2 completed small_molecule

Overactive Bladder

CT.gov ↗
NCT00345878
Placebo

Phase 3 completed mab

Infections, Papillomavirus

CT.gov ↗
NCT00345956
Human rotavirus liquid vaccine

Phase 3 completed mab

Infections, Rotavirus

CT.gov ↗
NCT00347009
adefovir dipivoxil

Approved completed small_molecule

Hepatitis B, Chronic

CT.gov ↗
NCT00347919
pazopanib (GW786034) 400 mg

Phase 2 completed small_molecule

Neoplasms, Breast

CT.gov ↗
NCT00348140
Rosiglitazone Extended Release 2mg

Phase 3 completed small_molecule

Alzheimer's Disease

CT.gov ↗
NCT00355082
lamotrigine, 300 mg/day

Phase 3 completed small_molecule

Epilepsy, Partial

CT.gov ↗
NCT00356369
meningococcal ACWY (vaccine)

Phase 2 completed mab

Infections, Meningococcal

CT.gov ↗
NCT00359463
eltrombopag

Phase 3 completed small_molecule

Purpura, Thrombocytopaenic, Idiopathic

CT.gov ↗
NCT00370331
eltrombopag

Phase 3 completed small_molecule

Purpura, Thrombocytopaenic, Idiopathic

CT.gov ↗
NCT00374322
lapatinib

Phase 3 completed small_molecule

Neoplasms, Breast

CT.gov ↗
NCT00379730
Prednisolone

Phase 1 completed small_molecule

Pulmonary Disease, Chronic Obstructive

CT.gov ↗
NCT00383383
Hepatitis B adjuvanted vaccine

Phase 3 completed mab

Hepatitis B

CT.gov ↗
NCT00387387
Pazopanib

Phase 1 completed small_molecule

Neoplasms, Colorectal

CT.gov ↗
NCT00400855
Fluticasone propionate

Phase 2 completed small_molecule

Asthma

CT.gov ↗
NCT00404768
GSK221149A

Phase 2 completed small_molecule

Obstetric Labour, Premature

CT.gov ↗
NCT00424255
Lapatinib

Phase 3 completed small_molecule

Neoplasms, Head and Neck

CT.gov ↗
NCT00430781
pazopanib (GW786034)

Phase 2 completed small_molecule

Neoplasms, Uterine Cervix

CT.gov ↗
NCT00432380
Rotarix™

Phase 2 completed mab

Infections, Rotavirus

CT.gov ↗
NCT00445510
GSK256066

Phase 2 completed small_molecule

Asthma

CT.gov ↗
NCT00449670
H5N1 adjuvanted split virus vaccine (A/Vietnam/1194/2004 strain)

Phase 3 completed mab

Influenza

CT.gov ↗
NCT00479739
Salmeterol/fluticasone propionate or formoterol/budesonide

Approved completed small_molecule

Asthma

CT.gov ↗
NCT00485069
ROP

Approved completed small_molecule

Parkinson Disease

CT.gov ↗
NCT00514904
Nimenrix

Phase 3 completed mab

Infections, Meningococcal

CT.gov ↗
NCT00516321
eltrombopag

Phase 3 completed small_molecule

Hepatitis C, Chronic

CT.gov ↗
NCT00540423
SB-497115-GR 12.5mg

Phase 3 completed small_molecule

Chronic Idiopathic Thrombocytopenic Purpura

CT.gov ↗
NCT00604825
Other: Placebo

Phase 2 completed small_molecule

Menopausal and Female Climacteric States

CT.gov ↗
NCT00676052
GSK233705 12.5mcg

Phase 2 completed small_molecule

Pulmonary Disease, Chronic Obstructive

CT.gov ↗
NCT00678587
Eltrombopag

Phase 3 terminated small_molecule

Non-alcoholic Steatohepatitis

CT.gov ↗
NCT00711776
New formulation

Phase 1 completed small_molecule

Herpes Labialis

CT.gov ↗
NCT00758264
Meningococcal vaccine GSK134612

Phase 3 completed mab

Infections, Meningococcal

CT.gov ↗
NCT00796445
GSK 2132231A

Phase 3 terminated small_molecule

Melanoma

CT.gov ↗
NCT00839527
placebo to match albiglutide

Phase 3 completed small_molecule

Diabetes Mellitus, Type 2

CT.gov ↗
NCT00879970
pioglitazone

Approved terminated small_molecule

Diabetes Mellitus, Type 2

CT.gov ↗
NCT00937404
Poliorix

Phase 1 completed mab

Poliomyelitis

CT.gov ↗
NCT00937950
Gynaecological follow-up

Phase 3 completed other

Infections, Papillomavirus

CT.gov ↗
NCT00976391
albiglutide + insulin glargine

Phase 3 completed mab

Diabetes Mellitus, Type 2

CT.gov ↗
NCT01009463
FF/GW642444 Inhalation Powder

Phase 3 completed small_molecule

Pulmonary Disease, Chronic Obstructive

CT.gov ↗
NCT01039805
GSK962040 50 mg

Phase 2 terminated small_molecule

Gastroparesis

CT.gov ↗
NCT01051661
GSK Biologicals' investigational vaccine GSK2340274A (alternative formulations)

Phase 3 completed mab

Influenza

CT.gov ↗
NCT01053988
FF/GW642444 Inhalation Powder

Phase 3 completed small_molecule

Pulmonary Disease, Chronic Obstructive

CT.gov ↗
NCT01098461
albiglutide

Phase 2 completed mab

Diabetes Mellitus, Type 2

CT.gov ↗
NCT01128569
Fluticasone Furoate

Phase 2 completed small_molecule

Asthma

CT.gov ↗
NCT01128595
FF/GW642444M

Phase 2 completed small_molecule

Asthma

CT.gov ↗
NCT01154088
Mencevax ACWY

Phase 3 completed mab

Infections, Meningococcal

CT.gov ↗
NCT01161160
GSK Biologicals' GSK2340274A (two different formulations)

Phase 2 completed mab

Influenza

CT.gov ↗
NCT01196988
Influenza vaccine GSK2321138A

Phase 3 completed mab

Influenza

CT.gov ↗
NCT01205178
Chloroquine

Phase 1 completed small_molecule

Malaria

CT.gov ↗
NCT01218308
FluLaval® Quadrivalent

Phase 3 completed mab

Influenza

CT.gov ↗
NCT01227889
GSK2118436

Phase 3 completed small_molecule

Cancer

CT.gov ↗
NCT01270958
Avamys aqueous nasal spray 110mcg

Approved completed small_molecule

Rhinitis, Allergic, Perennial

CT.gov ↗
NCT01277666
GSK1605786A

Phase 3 terminated small_molecule

Crohn's Disease

CT.gov ↗
NCT01310413
Influenza A (H5N1) Virus monovalent vaccine

Phase 3 completed mab

Influenza

CT.gov ↗
NCT01353703
Infanrix hexa™

Phase 3 completed mab

Poliomyelitis

CT.gov ↗
NCT01353742
Lamivudine

Phase 1 completed small_molecule

Hepatitis B, Chronic

CT.gov ↗
NCT01376245
fluticasone furoate/vilanterol

Phase 3 completed small_molecule

Pulmonary Disease, Chronic Obstructive

CT.gov ↗
NCT01379937
Influenza vaccine GSK1562902A Formulation 1

Phase 3 completed mab

Influenza

CT.gov ↗
NCT01445301
GSK2585823(CLDM 1%-BPO 3% gel)

Phase 3 completed small_molecule

Acne Vulgaris

CT.gov ↗
NCT01462669
50mg Ezogabine/retigabine

Phase 1 completed small_molecule

Epilepsy

CT.gov ↗
NCT01494610
SERETIDE Rotacaps

Phase 2 completed small_molecule

Asthma

CT.gov ↗
NCT01495000
denosumab

Phase 3 completed small_molecule

Osteoporosis, Postmenopausal

CT.gov ↗
NCT01498653
GW685698/GW642444

Phase 3 completed small_molecule

Asthma

CT.gov ↗
NCT01536418
GSK1605786A

Phase 3 terminated small_molecule

Crohn's Disease

CT.gov ↗
NCT01573624
FF/GSK573719

Phase 2 completed small_molecule

Asthma

CT.gov ↗
NCT01577732
Infanrix-IPV+Hib™

Phase 3 completed mab

Acellular Pertussis

CT.gov ↗
NCT01622231
Fluticasone furoate

Phase 3 completed small_molecule

Rhinitis

CT.gov ↗
NCT01745458
SB-659032

Phase 1 completed small_molecule

Atherosclerosis

CT.gov ↗
NCT01755689
Meningococcal vaccine GSK134612

Phase 3 completed mab

Infections, Meningococcal

CT.gov ↗
NCT01777269
Dutasteride plus tamsulosin

Approved completed small_molecule

Prostatic Hyperplasia

CT.gov ↗
NCT01928940
dabrafenib

Phase 2 completed small_molecule

Solid Tumours

CT.gov ↗
NCT01934192
GSK962040 50 mg

Phase 2 terminated small_molecule

Gastroparesis

CT.gov ↗
NCT02141217
Amoxicillin/clavulanate

Approved completed small_molecule

Focal Infection, Dental

CT.gov ↗
NCT02177812
GSK2879552

Phase 1 terminated small_molecule

Leukaemia, Myelocytic, Acute

CT.gov ↗
NCT02216123
Tafenoquine

Phase 3 completed small_molecule

Malaria, Vivax

CT.gov ↗
NCT02422264
Infanrix hexa

Approved completed mab

Acellular Pertussis

CT.gov ↗
NCT02424565
IODEX® balm

Approved completed small_molecule

Pain

CT.gov ↗
NCT02563496
Tafenoquine

Phase 3 completed small_molecule

Malaria, Vivax

CT.gov ↗
NCT02658422
Test Montelukast

Phase 1 completed small_molecule

Respiratory Disorders

CT.gov ↗
NCT02712047
Fluticasone furoate (FF) (100 mcg)

Phase 2 completed small_molecule

Asthma

CT.gov ↗
NCT02972905
GSK2269557 ELLIPTA DPI

Phase 1 completed small_molecule

Pulmonary Disease, Chronic Obstructive

CT.gov ↗
NCT03028467
GSK3196165 Dose 1

Phase 2 completed small_molecule

Arthritis, Rheumatoid

CT.gov ↗
NCT03150056
GSK525762

Phase 1 terminated small_molecule

Solid Tumours

CT.gov ↗
NCT03493386
Daprodustat 2 mg tablet

Phase 1 completed small_molecule

Anaemia

CT.gov ↗
NCT03980483
GSK3196165 (Otilimab)

Phase 3 completed mab

Arthritis, Rheumatoid

CT.gov ↗
NCT04187144
Gepotidacin

Phase 3 completed small_molecule

Urinary Tract Infections

CT.gov ↗
NCT04605159
RSV MAT

Phase 3 terminated mab

Respiratory Syncytial Virus Infections

CT.gov ↗
NCT04915755
Niraparib

Phase 3 active small_molecule

Neoplasms, Breast

CT.gov ↗
NCT05630807
Bepirovirsen

Phase 3 completed small_molecule

Chronic Hepatitis B

CT.gov ↗
NCT05757102
FF/UMEC/VI

Phase 3 active small_molecule

Asthma

CT.gov ↗
NCT05999799
GSK1070806

Phase 2 terminated small_molecule

Dermatitis, Atopic

CT.gov ↗
NCT06079190
GSK4527226

Phase 2 active small_molecule

Alzheimer's Disease

CT.gov ↗
NCT06256588
Dostarlimab

Phase 3 active small_molecule

Neoplasms, Head and Neck

CT.gov ↗
NCT06261957
Salbutamol HFA-134a

Phase 3 completed small_molecule

Asthma

CT.gov ↗
NCT06868667
Belantamab mafodotin

Phase 3 active small_molecule

Multiple Myeloma

CT.gov ↗
NCT07438782
GSK5533524

Phase 1 active small_molecule

Neoplasms

CT.gov ↗